Plain-language summaries of the published literature on the compounds we sell — written for laboratory reference, not as medical guidance. Every article ends with a research-use-only disclaimer because that is the only context in which this material applies.
How research peptides degrade, what slows it down, and the temperature, light, and freeze-thaw considerations that determine whether a vial stays viable for weeks or months in a research setting.
How lyophilized peptide vials behave when rehydrated, why bacteriostatic water exists, and the laboratory-handling considerations researchers use to preserve compound integrity.
A profile of Melanotan-2: the cyclic α-MSH analog, its non-selective melanocortin receptor activity, and how it differs from Melanotan I and PT-141.
A profile of ipamorelin: the pentapeptide ghrelin-receptor agonist that releases growth hormone without the cortisol spikes of the older GHRPs.
A lab-reference profile of NAD+: the redox coenzyme's structure, why it degrades so fast in solution, its inverse pH stability, and the precursor debate.
What GLP-3 RT is at the molecular level: the GIP/GLP-1/glucagon triple agonist known in the literature as retatrutide, its lipidation, half-life, and handling.
A profile of tesamorelin: the GHRH(1-44) analog with an N-terminal hexenoyl cap, how its half-life and stability compare to CJC-1295, and handling notes.
An overview of the GHK-Cu literature: the tripeptide-copper complex, why the blue color matters analytically, and the copper-specific handling rules.
What TB-500 actually is at the molecular level, the actin-binding mechanism behind the literature, and the storage rules for a 43-amino-acid peptide.
An overview of the BPC-157 literature, the molecule's structural features, what is known about its stability under different conditions, and laboratory-handling notes for research use.
Semax and Selank share a Pro-Gly-Pro tail but descend from different parents — ACTH and tuftsin. How the two compare in structure, mechanism, and storage.
How BPC-157 and TB-500 differ in mechanism and research-design context, where their literatures overlap, and how to read combination-protocol papers.
What the drug-affinity complex (DAC) modification actually does to CJC-1295, how it changes the molecule's plasma half-life, and the experimental-design implications for research work.
HelixCore Biotech
Diese Website enthält Forschungsmaterialien. Mit dem Betreten bestätigen Sie, dass Sie 18 Jahre oder älter sind und unsere AGB sowie den RUO-Hinweis akzeptieren.